Genetic mismatch affects the immunosuppressive properties of mesenchymal stem cells in vitro and their ability to influence the course of collagen-induced arthritis

Hdl Handle:
http://hdl.handle.net/10147/265419
Title:
Genetic mismatch affects the immunosuppressive properties of mesenchymal stem cells in vitro and their ability to influence the course of collagen-induced arthritis
Authors:
Sullivan, Catherine; Murphy, J Mary; Griffin, Matthew D; Porter, Ryan M; Evans, Christopher H; O'Flatharta, Cathal; Shaw, Georgina; Barry, Frank
Citation:
Arthritis Research & Therapy. 2012 Jul 19;14(4):R167
Issue Date:
19-Jul-2012
URI:
http://dx.doi.org/10.1186/ar3916; http://hdl.handle.net/10147/265419
Abstract:
Abstract Introduction The immunological and homing properties of mesenchymal stem cells (MSCs) provide a potentially attractive treatment for arthritis. The objective of this study was to determine effects of genetic disparity on the immunosuppressive potential of MSCs in vitro and in vivo within collagen induced arthritis (CIA). Methods The ability of DBA/1, FVB and BALB/c MSC preparations to impact the cytokine release profile of CD3/CD28 stimulated DBA/1 T cells was assessed in vitro. The effect of systemically delivered MSCs on the progression of CIA and cytokine production was assessed in vivo. Results All MSC preparations suppressed the release of TNFα and augmented the secretion of IL-4 and IL-10 by stimulated DBA/1 T-cells. However, assessment of the ratio of IFNγ to IL-4 production indicated that the more genetically distant BALB/c MSCs had significantly less immunosuppressive capacity. Systemic delivery of BALB/c MSC resulted in an exacerbation of CIA disease score in vivo and a higher erosive disease burden. This was not seen after treatment with syngeneic or partially mismatched MSCs. An increase in serum levels of IL-1β was observed up to 20 days post treatment with allogeneic MSCs. An initial elevation of IL-17 in these treatment groups persisted in those treated with fully mismatched BALB/c MSCs. Over the course of the study, there was a significant suppression of serum IL-17 levels in groups treated with syngeneic MSCs. Conclusions These data demonstrate a significant difference in the immunosuppressive properties of syngeneic and allogeneic MSCs in vitro and in vivo, which needs to be appreciated when developing MSC based therapies for inflammatory arthritis.
Item Type:
Journal Article

Full metadata record

DC FieldValue Language
dc.contributor.authorSullivan, Catherine-
dc.contributor.authorMurphy, J Mary-
dc.contributor.authorGriffin, Matthew D-
dc.contributor.authorPorter, Ryan M-
dc.contributor.authorEvans, Christopher H-
dc.contributor.authorO'Flatharta, Cathal-
dc.contributor.authorShaw, Georgina-
dc.contributor.authorBarry, Frank-
dc.date.accessioned2013-01-15T09:05:26Z-
dc.date.available2013-01-15T09:05:26Z-
dc.date.issued2012-07-19-
dc.identifier.citationArthritis Research & Therapy. 2012 Jul 19;14(4):R167-
dc.identifier.urihttp://dx.doi.org/10.1186/ar3916-
dc.identifier.urihttp://hdl.handle.net/10147/265419-
dc.description.abstractAbstract Introduction The immunological and homing properties of mesenchymal stem cells (MSCs) provide a potentially attractive treatment for arthritis. The objective of this study was to determine effects of genetic disparity on the immunosuppressive potential of MSCs in vitro and in vivo within collagen induced arthritis (CIA). Methods The ability of DBA/1, FVB and BALB/c MSC preparations to impact the cytokine release profile of CD3/CD28 stimulated DBA/1 T cells was assessed in vitro. The effect of systemically delivered MSCs on the progression of CIA and cytokine production was assessed in vivo. Results All MSC preparations suppressed the release of TNFα and augmented the secretion of IL-4 and IL-10 by stimulated DBA/1 T-cells. However, assessment of the ratio of IFNγ to IL-4 production indicated that the more genetically distant BALB/c MSCs had significantly less immunosuppressive capacity. Systemic delivery of BALB/c MSC resulted in an exacerbation of CIA disease score in vivo and a higher erosive disease burden. This was not seen after treatment with syngeneic or partially mismatched MSCs. An increase in serum levels of IL-1β was observed up to 20 days post treatment with allogeneic MSCs. An initial elevation of IL-17 in these treatment groups persisted in those treated with fully mismatched BALB/c MSCs. Over the course of the study, there was a significant suppression of serum IL-17 levels in groups treated with syngeneic MSCs. Conclusions These data demonstrate a significant difference in the immunosuppressive properties of syngeneic and allogeneic MSCs in vitro and in vivo, which needs to be appreciated when developing MSC based therapies for inflammatory arthritis.-
dc.titleGenetic mismatch affects the immunosuppressive properties of mesenchymal stem cells in vitro and their ability to influence the course of collagen-induced arthritis-
dc.typeJournal Article-
dc.language.rfc3066en-
dc.rights.holderCatherine Sullivan et al.; licensee BioMed Central Ltd.-
dc.description.statusPeer Reviewed-
dc.date.updated2013-01-14T13:10:03Z-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.